Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Dustin Blitchok

EXCLUSIVE: How Cybin Is Developing The Next Generation Of Psychedelics

If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE:CYBN) is many trips ahead of you.

The Toronto-based company is studying derivatives of psilocybin and DMT and plans to file an investigational new drug application with the FDA during this quarter, CEO Doug Drysdale said Tuesday at the inaugural Benzinga Psychedelics Capital Conference.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.